Avidity characterization of genetically engineered T-cells with novel and established approaches.

about

Pro-inflammatory allogeneic DCs promote activation of bystander immune cells and thereby license antigen-specific T-cell responses.In vitro immunotherapy potency assays using real-time cell analysis.

P2860

Q50535283-5A6935CD-3615-49E4-A387-54193BD75F57 Q52369403-9770DDF5-5FB3-4EAB-A022-AE8EE65DFB28

P2860

Avidity characterization of genetically engineered T-cells with novel and established approaches.

Item

http://www.wikidata.org/entity/Q36076472

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Avidity characterization of ge ...... el and established approaches.

@ast

Avidity characterization of ge ...... el and established approaches.

@en

type

Item

label

Avidity characterization of ge ...... el and established approaches.

@ast

Avidity characterization of ge ...... el and established approaches.

@en

prefLabel

Avidity characterization of ge ...... el and established approaches.

@ast

Avidity characterization of ge ...... el and established approaches.

@en

P1476

Avidity characterization of ge ...... el and established approaches.

@en

P2093

Hanna Björkelund

http://www.w3.org/2001/XMLSchema#string

Karl Andersson

http://www.w3.org/2001/XMLSchema#string

Magnus Essand

http://www.w3.org/2001/XMLSchema#string

Vanessa F Boura

http://www.w3.org/2001/XMLSchema#string

Victoria Hillerdal

http://www.w3.org/2001/XMLSchema#string

P2860

PD-1/PD-L1 blockade in cancer treatment: perspectives and issues

To affinity and beyond: harnessing the T cell receptor for cancer immunotherapy

Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia

Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2

Different affinity windows for virus and cancer-specific T-cell receptors: implications for therapeutic strategies

Neoantigens in cancer immunotherapy.

A constant affinity threshold for T cell tolerance.

T cells engineered with a T cell receptor against the prostate antigen TARP specifically kill HLA-A2+ prostate and breast cancer cells

Functionally inert HIV-specific cytotoxic T lymphocytes do not play a major role in chronically infected adults and children

Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy.

P2888

s12865-016-0162-z

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S12865-016-0162-Z

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-07-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1024648000

http://www.w3.org/2001/XMLSchema#string

P698

27411667

http://www.w3.org/2001/XMLSchema#string

P932

4944473

http://www.w3.org/2001/XMLSchema#string

Avidity characterization of genetically engineered T-cells with novel and established approaches.

about

P2860

P2860

Avidity characterization of genetically engineered T-cells with novel and established approaches.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P932